Medical Devices

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

In under two years, Cynosure Lutronic's XERF device has tripled its adoption rate, signaling a major shift in the multi-billion dollar aesthetics industry.

Hainan's new medical tourism hub is more than a hospital—it's a strategic play for global dominance, using exclusive drugs and VIP service to lure patients.

As Kewaunee Scientific preps its year-end report, all eyes are on whether its bold Nu Aire acquisition can translate revenue gains into long-term profit.

A new partnership between Daybreak and VHSS isn't just about a new device; it’s a durable model for delivering resilient healthcare solutions to veterans.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

Beacon Biosignals is merging AI-driven brain monitoring with home sleep testing, creating a powerful new platform that could redefine neurological diagnostics.

A new Florida venture embeds sleep apnea treatment into cardiology care, a model that could reshape patient outcomes and Vivos Therapeutics' market strategy.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

A new partnership brings NEJM to a physician-only network, challenging AI's grip on medical knowledge and betting on the value of human discussion.

HOPPR's Catalyst Program is arming global researchers with advanced tools, accelerating AI projects from cancer detection in Africa to risk prediction in the US.

DuPont now powers its US healthcare plants with 100% renewables, a key move in a carbon-heavy sector. But a look behind the certificates reveals a complex strategy.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

The Ohio manufacturer's management buyout signals a shift from private equity cycles to long-term agility in a booming precision components market.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.

As AI fatigue hits markets, one sector sees a real breakthrough. Taiwan's TFC is using AI to boost IVF success, offering new hope to infertile couples.